Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bloating

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    111 result(s) found for: Bloating. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2006-002963-23 Sponsor Protocol Number: Not available Start Date*: 2006-08-03
    Sponsor Name:Chr. Hansen A/S
    Full Title: The effect of probiotics on bloating in IBS
    Medical condition: Meteorism symptoms in women dominated by bloating
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004977-42 Sponsor Protocol Number: CB-01-11/28 Start Date*: 2017-11-10
    Sponsor Name:Cosmo Technologies Ltd.
    Full Title: A Phase II, multicentre, randomised, double-blind, placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily to pat...
    Medical condition: Diarrhoea-predominant irritable bowel syndrome (IBS-D)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Temporarily Halted) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001355-12 Sponsor Protocol Number: LPS15198 Start Date*: 2019-02-27
    Sponsor Name:SANOFI-AVENTIS GROUPE
    Full Title: Phase IV, randomized, double-blind, multicenter, placebo-controlled clinical trial to evaluate the efficacy and the safety of enterogermina (Bacillus clausii) in treating patients with small intest...
    Medical condition: Small intestinal bacterial overgrowth (SIBO)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10071061 Small intestinal bacterial overgrowth LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002143-15 Sponsor Protocol Number: RLM-MD-03 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) LV (Prematurely Ended) HU (Completed) FR (Completed) BE (Completed) DK (Prematurely Ended) BG (Completed) AT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000436-24 Sponsor Protocol Number: AGI006-001 Start Date*: 2005-04-08
    Sponsor Name:AGI Therapeutics Limtied
    Full Title: A randomised, double-blind, placebo-controlled study of AGI 006 in the treatment of functional dyspepsia.
    Medical condition: Functional (Non-ulcer) Dyspepsia (FD; NUD)
    Disease: Version SOC Term Classification Code Term Level
    6.0 10013946 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002762-38 Sponsor Protocol Number: Clin-AGI001-001 Start Date*: 2005-04-13
    Sponsor Name:AGI Therapeutics Limited
    Full Title: A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of functional dyspepsia
    Medical condition: Functional (Non-ulcer) Dyspepsia
    Disease: Version SOC Term Classification Code Term Level
    7.0 10001394 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003257-16 Sponsor Protocol Number: CitraFleet_H-2018 Start Date*: 2018-11-07
    Sponsor Name:Goodwill Pharma Kft.
    Full Title: Efficacy, Safety and Tolerability of CitraFleet, a New Bowel Cleansing Agent – a Prospective, Single-Center, Single-Group Phase IV Study
    Medical condition: Colonoscopy bowel preparation
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10017963 Gastrointestinal and abdominal imaging procedures HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-002177-20 Sponsor Protocol Number: RLM-MD-02 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) LV (Prematurely Ended) HU (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) AT (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002136-16 Sponsor Protocol Number: RLM-MD-01 Start Date*: 2019-04-02
    Sponsor Name:Allergan Ltd.
    Full Title: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002144-33 Sponsor Protocol Number: RLM-MD-04 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) FR (Completed) BE (Completed) BG (Prematurely Ended) DK (Completed) AT (Prematurely Ended) LV (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002594-33 Sponsor Protocol Number: TZP-102-CL-G003 Start Date*: 2011-10-14
    Sponsor Name:Tranzyme, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP 102 for the Treatment of Symptoms Associated w...
    Medical condition: The medical condition to be investigated is symptomatic gastroparesis due to diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002394-22 Sponsor Protocol Number: RFIB3053 Start Date*: 2013-09-26
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhoea (IBS-D)
    Medical condition: Irritable bowel syndrome (IBS) is a heterogeneous gastrointestinal (GI) disorder characterized by frequent and debilitating symptoms (e.g. diarrhoea, bloating, abdominal pain, urgency to defecate, ...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015728-27 Sponsor Protocol Number: AH-IBS-005 Start Date*: 2009-11-13
    Sponsor Name:Alimentary Health Ltd
    Full Title: A Double Blind, Randomised, placebo-contoled Trial to establish teh safety and efficacy of a probiotic in subjects with Irritable Bowel Syndrome
    Medical condition: Irritable bowel Syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002748-25 Sponsor Protocol Number: ICP-112-201 Start Date*: 2012-10-25
    Sponsor Name:Ironwood Pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once Daily for 14 Days to Patients with Functional Dyspepsia
    Medical condition: Functional Dyspepsia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002851-92 Sponsor Protocol Number: AN-EPI3334 Start Date*: 2016-09-08
    Sponsor Name:ANTHERA Pharmaceuticals, Inc.
    Full Title: An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis
    Medical condition: Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Completed) PL (Prematurely Ended) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002576-14 Sponsor Protocol Number: TZP-102-CL-G004 Start Date*: 2012-08-23
    Sponsor Name:Tranzyme, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associate...
    Medical condition: The medical condition to be investigated is symptomatic gastroparesis due to diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004519-31 Sponsor Protocol Number: ENTERL08784 Start Date*: 2019-01-31
    Sponsor Name:Sanofi
    Full Title: Randomized, placebo-controlled, clinical trial to evaluate the efficacy of probiotic Bacillus clausii in the treatment of pediatric patients with irritable bowel syndrome
    Medical condition: Irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000818-29 Sponsor Protocol Number: MCP-103-403 Start Date*: 2016-08-08
    Sponsor Name:Ironwood Pharmaceuticals, Inc.
    Full Title: A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants with Irritable Bowel Syndrom...
    Medical condition: Irritable Bowel Syndrome with Constipation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10066868 Constipation predominant irritable bowel syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000854-24 Sponsor Protocol Number: VE-CIP2001/2021 Start Date*: 2021-12-21
    Sponsor Name:ALFASIGMA S.P.A.
    Full Title: Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial.
    Medical condition: Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture si...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001793-15 Sponsor Protocol Number: Gastro_CHU_16-1 Start Date*: 2016-07-12
    Sponsor Name:LactoResearch sprl
    Full Title: PROSPECTIVE STUDY OF THE EFFICIENCY OF PROBIOTIC MIXTURE TO IMPROVE LACTOSE DIGESTION AND SYMPTOMS OF LACTOSE INTOLERANCE
    Medical condition: lactose intolerance
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10023682 Lactose intolerant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 00:46:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA